The company announced its acquisition of Wright Medical in November 2019. Since then, the FTC increased its scrutiny of the proposed merger in January, a Wright Medical shareholder filed a proposed class-action lawsuit to block the acquisition later that month and the U.K. began a probe into the merger last month.
Also in May, Stryker announced that it entered into an underwriting agreement in connection with a $2.3 billion offering set to finance the acquisition.
Stryker’s indirect, wholly-owned subsidiary, Stryker B.V., officially extended the offering period until an expiration date of 5 p.m. ET on Aug. 31, 2020, unless it is further extended or earlier terminated.
According to a news release, as of June 26, more than 10.4 million Wright Medical ordinary shares, representing 8.1% of the outstanding shares, have been validly tendered and not properly withdrawn. Additionally, more than 1.1 million shares (0.9% of the outstanding shares) had been tendered pursuant to guaranteed delivery procedures.